Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin

REFERENCES

• MacKinnon AC, Kopatz J, Sethi T: The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. Br Med Bull. 2010;95:47–61.
   PubMed Web of Science ®Google Scholar
• Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res. 2004;10:4210s–4214s.
   PubMed Web of Science ®Google Scholar
• Adhikari AS, Agarwal N, Iwakuma T: Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci. 2011;16:1927–1938.
   Web of Science ®Google Scholar
• Tomuleasa C, Kacso G, Soritau O, Susman S, Petrushev B, Aldea M, Buiga R, Irimie A: The fundamental mechanisms of metastatic spread and chemotherapy resistance in lung cancer. Pneumologia. 2011;60:99–103.
   PubMedGoogle Scholar
• Soltanian S, Matin MM: Cancer stem cells and cancer therapy. Tumour Biol. 2011;32:425–440.
   PubMed Web of Science ®Google Scholar
• Gorelik E, Lokshin A, Levina V: Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem. 2010;10:164–171.
   PubMed Web of Science ®Google Scholar
• Alison MR, Lebrenne AC, Islam S: Stem cells and lung cancer: future therapeutic targets? Expert Opin Biol Ther. 2009;9:1127–1141.
   PubMed Web of Science ®Google Scholar
• Pine SR, Marshall B, Varticovski L: Lung cancer stem cells. Dis Markers. 2008;24:257–266.
   PubMed Web of Science ®Google Scholar
• Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K: Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma–their prognostic significance. Pathol Int. 2012;62:792–801.
   PubMed Web of Science ®Google Scholar
• Karimi-Busheri F, Zadorozhny V, Li T, Lin H, Shawler DL, Fakhrai H: Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J Stem Cells. 2011;6:9–20.
   PubMedGoogle Scholar
• Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–514.
   PubMed Web of Science ®Google Scholar
• Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 2008;3:e3077.
   PubMed Web of Science ®Google Scholar
• Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 2009;106:16281–16286.
   PubMed Web of Science ®Google Scholar
• Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S: Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1; p53-deficient mammary tumor cells in vivo. Cell Cycle. 2010;9:3780–3791.
   Google Scholar
• Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, Zhang Z, Olson JJ, Hao C: Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest. 2011;29:511–520.
   PubMed Web of Science ®Google Scholar
• Rahman M, Deleyrolle L, Vedam-Mai V, Azari H, Abd-El-Barr M, Reynolds BA: The cancer stem cell hypothesis: failures and pitfalls. Neurosurgery. 2011;68:531–545; discussion 545.
   PubMed Web of Science ®Google Scholar
• Delude C: Tumorigenesis: testing ground for cancer stem cells. Nature. 2011;480:S43–S45.
   Google Scholar
• van Klaveren RJ, van't Westeinde SC, de Hoop BJ, Hoogsteden HC: Stem cells and the natural history of lung cancer: implications for lung cancer screening. Clin Cancer Res. 2009;15:2215–2218.
   PubMed Web of Science ®Google Scholar
• Sakashita H, Ieta K, Haraguchi N, Inoue Y, Yoshizawa Y, Mori M: Cancer stem cell. Gan To Kagaku Ryoho. 2007;34:1721–1729.
   PubMedGoogle Scholar
• Aonuma M, Saeki Y, Akimoto T, Nakayama Y, Hattori C, Yoshitake Y, Nishikawa K, Shibuya M, Tanaka NG: Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression. Int J Exp Pathol. 1999;80:271–281.
   PubMed Web of Science ®Google Scholar
• Hofer EL, La Russa V, Honegger AE, Bullorsky EO, Bordenave RH, Chasseing NA: Alteration on the expression of IL-1, PDGF, TGF-beta, EGF, and FGF receptors and c-Fos and c-Myc proteins in bone marrow mesenchymal stroma cells from advanced untreated lung and breast cancer patients. Stem Cells Dev. 2005;14:587–594.
   PubMed Web of Science ®Google Scholar
• Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, Contag PR: Bioluminescent imaging (BLI) to improve and refine traditional murine of tumor growth and metastasis. Clin Exp Metastas. 2003;20:733–744.
   PubMed Web of Science ®Google Scholar
• Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty J. D, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One. 2013;8(1);e54193.
   PubMed Web of Science ®Google Scholar
• Wang S, Li W, Xue Z, Narsinh K, Fan W, Li X, Bu Q, Wang F, Liang J, Wu K, Cao F: Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinogen. 2013;52:900–907.
   PubMedGoogle Scholar
• Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–1806.
   PubMed Web of Science ®Google Scholar
• Xue Z, Yan H, Li J, Liang S, Cai X, Chen X, Wu Q, Gao L, Wu K, Nie Y, Fan D: Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem. 2012;113:302–312.
   PubMed Web of Science ®Google Scholar
• Huysentruyt LC, Shelton LM, Seyfried TN: Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Int J Cancer. 2009;126:65–72.
   Web of Science ®Google Scholar
• Choi E, Carruthers K, Zhang L, Thomas N, Battaglino RA, Morse LR, Widrick JJ: Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep. 2013;1(6):e00144.
   Google Scholar
• Cao F, Lin S, Xie X, Patel M, Zhang X, Drukker M, Dylla SJ, Connolly AJ, Chen X, Weissman IL, Gambhir SS, Wu JC: In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation. 2006;113:1005–1014.
   PubMed Web of Science ®Google Scholar
• Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z: PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1–11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53:144–156.
   PubMed Web of Science ®Google Scholar
• Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008;3:e2637.
   PubMed Web of Science ®Google Scholar
• Glinsky GV: “Stemness” genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008;26:2846–2853.
   PubMed Web of Science ®Google Scholar
• Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, Miele L, Bocchetta M: Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010;29:2488–2498.
   PubMed Web of Science ®Google Scholar
• Moreira AL, Gonen M, Rekhtman N, Downey RJ: Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol. 2010;23:889–895.
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Kohyama T, Takizawa H, Kamitani S, Desaki M, Takami K, Kawasaki S, Kato J, Nagase T: Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Exp Lung Res. 2010;36:12–24.
   PubMed Web of Science ®Google Scholar
• Karlic H, Herrmann H, Schulenburg A, Grunt TW, Laffer S, Mirkina I, Hubmann R, Shehata M, Marian B, Selzer E, Pfeilstöcker M, Pittermann E, Jäger U, Pehamberger H, Zielinski C, Valent P: Tumor stem cell research - basis and challenge for diagnosis and therapy. Wien Klin Wochenschr. 2010;122:423–436.
   PubMed Web of Science ®Google Scholar
• Baguley BC: Multidrug resistance in cancer. Methods Mol Biol. 2010;596:1–14.
   PubMedGoogle Scholar
• Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 2010;126:950–958.
   PubMed Web of Science ®Google Scholar
• Hsu HS, Lin JH, Huang WC, Hsu TW, Su K, Chiou SH, Tsai YT, Hung SC: Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer. 2011;117:1516–1528.
   Web of Science ®Google Scholar
• Meng X, Li M, Wang X, Wang Y, Ma D: Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 2009;100:1040–1046.
   PubMed Web of Science ®Google Scholar
• Visvader JE: Cells of origin in cancer. Nature. 2011;469: 314–322.
   PubMed Web of Science ®Google Scholar
• Visvader JE: Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009;23:2563–2577.
   PubMed Web of Science ®Google Scholar
• Huysentruyt LC, Shelton LM, Seyfried TN: Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. Int J Cancer. 2010;126:65–72.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Hauke R, Mehta PP, Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007;11:981–1011.
   PubMed Web of Science ®Google Scholar
• Deonarain MP, Kousparou CA, Epenetos AA: Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs. 2009;1:12–25.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ravula R, Cao M, Chow M, Huang Y: Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products. Curr Drug Discov Technol. 2010;7:54–66.
   PubMedGoogle Scholar
• Natarajan K, Xie Y, Baer MR, Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83:1084–1103.
   PubMed Web of Science ®Google Scholar
• Seo DC, Sung JM, Cho HJ, Yi H, Seo KH, Choi IS, Kim DK, Kim JS, El-Aty Am A, Shin HC: Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer. 2007;6:75–82.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Ross DD: Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31: 73–99.
   PubMed Web of Science ®Google Scholar